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Abstract 
AIM: In order to examine the clinical effect of four anti-dementia drugs (donepezil, galantamine, 
rivastigmine, and memantine) in Alzheimer’s disease (AD) patients who were divided into subgroups 
based on their periventricular hyperintensity (PVH)-severity. 
METHODS: 551 AD patients (201 males and 350 females) were divided into four subgroups based 
on their PVH-severity (0-III). They received monotherapy for 12 months (M). We compared the 
clinical effects at the baseline and at 3, 6, and 12 M after initiation.  
RESULTS: The baseline age became higher with PVH grades, and the mini-mental state examination 
(MMSE) and Hasegawa dementia scale-revised (HDS-R) showed a decrease that was dependent on 
white matter (WM) severity. Although the PVH 0 subgroup showed stable cognitive, affective, and 
ADL functions until 12 M in all four drug groups, the PVH I subgroup showed an improved apathy 
scale (AS) from the baseline in response to memantine at 3 and 9 M (p < 0.05), and galantamine at 9 
M (p < 0.01). In the PVH II subgroup, MMSE showed a significant improvement from the baseline in 
response to galantamine (p < 0.05) at 9 M and HDS-R (p < 0.05) at 3 M. In the PVH III subgroup, 
cognitive and affective functions were preserved in all four drug groups until 12 M, but ADL 
deteriorated in the riverstigmine group at 6 and 12 M (p < 0.05).  
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CONCLUSIONS: The present study demonstrates that these four drugs showed sensitivity dependent 
on WM severity that clinically affected cognitive, affective and ADL functions. 
Keywords: Alzheimer’s disease, anti-dementia drug, magnetic resonance imaging, periventricular 
hyperintensity, white matter lesions 
Introduction 
As a result of a rapidly aging world population, dementia has become a significant social 
priority. Alzheimer’s disease (AD) is the most common cause of dementia, and is a neurodegenerative 
disease characterized by the presence of amyloid-beta (Aβ) plaques with neuritic plaques and 
neurofibrillary tangles that add to the severity of these changes 1. 
White matter lesions (WMLs), including periventricular hyperintensity (PVH) and deep 
white matter hyperintensity (DWMH), are visualized as an increased signal on T2-weighted and 
fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) sequences 2, and are 
observed in normal elderly adults as well as in AD patients. In a previous report, WMLs are associated 
with clinical risk and a symptomatic course of AD 3. The volume of PVH was also associated with 
neurofibrillary tangles and the volume of DWMH was associated with diffuse plaques indicating that 
AD pathology may contribute to the vascular or white matter pathology 4. Notably, our previous 
studies demonstrated that the severity of WMLs was closely related to AD pathology, and strongly 
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influenced the deterioration of cognitive and affective functions in AD patients 5, 6. Early stage AD 
patients may be more vulnerable to the cognitive effect of WHLs than cognitively normal elderly 
adults with a similar burden of WHLs 7. 
Although there has been much debate about the relation between AD pathology and WMLs, 
there is no report on the WML-dependent effectiveness of drugs on AD patients. In the present study, 
therefore, we examined the clinical effect of four anti-dementia drugs (donepezil, galantamine, 
rivastigmine, and memantine) in AD patients who were divided into subgroups based on their PVH 
severity. 
 
 
Materials and Methods 
Participants and study design 
This was a retrospective clinical cohort study performed in the outpatient clinic of 
Okayama University Hospital and affiliated hospitals from June 2011 to March 2016. For the present 
study, we recruited 551 AD patients (201 males and 350 females; 78.4 ± 7.3 years old, mean ± SD) 
that were on monotherapy with donepezil, galantamine, rivastigmine, or memantine. All patients are 
prescribed anti-AD drugs for the first time. Those patients that were receiving combination therapy or 
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that switched to a combination therapy of cholinesterase inhibitor plus memantine were excluded from 
this study. AD patients were diagnosed with probable or possible AD according to the National 
Institute of Neurological and Communicative Disorders and Stroke AD and Related Disorders 
Association (NINCDS-ADRDA). Magnetic resonance imaging (MRI) was used to estimate changes in 
white matter (WM) with PVH using the Fazekas scale 8 on T2 weighted images (T2WI) and fluid 
attenuated inversion recovery (FLAIR) images, and were divided into four subgroups according to the 
grade of PVH (0-III). Furthermore, parahippocampal gyrus atrophy of each PVH group was evaluated 
using Z score of the voxel-based specific regional analysis system for Alzheimer’s disease (VSRAD) 9 
which become an indicator reflecting the degree of the entorhinal cortex for diagnosis of early AD 10. 
The drug dose was gradually increased as follows: donepezil, from 3 to 5 or 10 mg; 
galantamine, from 8 to 16 or 24 mg over 4 or 8 weeks; rivastigmine, from 4.5 to 18 mg over 16 weeks; 
memantine, from 5 to 20 mg over 4 weeks. Cognitive functions were assessed using the mini-mental 
state examination (MMSE) and Hasegawa dementia scale-revised (HDS-R). The behavioral and 
psychological symptoms of dementia (BPSD) were assessed using the 15-item geriatric depression 
scale (GDS) for depression, the apathy scale (AS) for apathy, and Abe’s BPSD score (ABS) 11. In 
addition, the activities of daily living (ADL) were assessed using the Alzheimer’s Disease Cooperative 
Study-Activities of Daily Living (ADCS-ADL). These scores were assessed at the baseline and at 3, 6, 
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and 12 months (M) after initiation (12 M as a whole). 
Ethical permission for this study was provided by the Ethics Committee on 
Epidemiological Studies of the Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences (approval #775), and written informed consent was obtained from all 
participants prior to enrollment. 
 
Statistical analysis 
Demographic and clinical data are presented as mean ± S.D. in the text and tables. 
Statistical analyses were performed using statistical software (SPSS 22.0.0.0; IBM, Armonk, New 
York, USA). Differences in the distribution of demographic factors among PVH grades (0 - III) were 
analyzed using the χ2 test and Jonckheere-Terpstra’s test. After having checked for normality, baseline 
age, Z scores of VSRAD and six clinical scores (i.e., MMSE, HDS-R, GDS, AS, ABS, and 
ADCS-ADL) were compared using the Kraskal-Wallis test among PVH grades (0 - III) or 
anti-dementia drugs. Similarly, changes from the baseline at each time point were compared using the 
Kraskal-Wallis test among anti-dementia drugs. P-values < 0.05 were considered to be significantly 
different. 
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Results 
Participants’ characteristics 
The baseline demographic and clinical features of all AD patients (n=551) and each group 
according to the grade of PVH (0-III) are shown in Table 1. The ratio of females among the 551 AD 
patients was 63.5 % and the average age of all AD patients was 78.4 ± 7.3 years old (yo, mean ± SD). 
The number of patients in each PVH groups was as follows: PVH 0; n=41, PVH I; n=212, PVH II; 
n=179, PVH III; n=119. Although there were no differences in the gender ratio, Z score of VSRAD, 
emotional scores (GDS, AS, ABS) or ADL in the four PVH subgroups, the baseline age showed a 
WM-severity-dependent increase: 72.2 ± 8.1 yo for PVH 0, 77.5 ± 6.8 yo for PVH I, 79.6 ± 6.7 yo for 
PVH II, and 80.5 ± 7.4 yo for PVH III (** p < 0.01 vs PVH 0, ## p < 0.01 vs PVH I, and p-value for 
increasing trend < 0.001). In contrast, cognitive scores showed a WM-severity-dependent decreases in 
MMSE (21.1 ± 4.2 for PVH 0, 21.0 ± 4.6 for PVH I, 19.4 ± 5.3 for PVH II, and 19.2 ± 4.6 for PVH 
III), and HDS-R (19.2 ± 5.6 for PVH 0, 19.0 ± 5.7 for PVH I, 16.7 ± 6.2 for PVH II, and 16.7 ± 5.3 for 
PVH III) (# p < 0.05 vs PVH I, ## p < 0.01 vs PVH I, and p-value for increasing trend < 0.001).  
Table 2 shows the change of each drug dosage (mg/day) from 3 to 12 M, and baseline 
PVH-severity-dependent features of AD patients in the four drug subgroups. The average drug dosage 
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showed a progressive increase from 3 to 12 M in all four drugs (Table 2, top). Finally, 249 patients 
dropped out or were lost to follow up, and 302 patients remained. The number of patients in each drug 
subgroup was showed in Table 2 (the digit in parentheses shows the number of patients in each term). 
In the PVH 0 subgroup (n=41), the rivastigmine group showed a higher baseline ABS (12.3 ± 10.0) 
than the donepezil group (2.1 ± 3.1, * p < 0.05). In the PVH I subgroup (n=212), the memantine group 
showed a higher baseline ABS (9.8 ± 6.9) than the donepezil group (2.8 ± 3.9, * p < 0.05) and the 
galantamine group (3.2 ± 4.4, # p < 0.05). In the PVH II subgroup (n=179), the memantine group 
(12.0 ± 9.3) again showed a higher baseline ABS (12.0 ± 9.3) than the donepezil group (3.1 ± 5.4, * p 
< 0.05). There were no significant differences in the baseline age and other baseline scores. 
 
Changes from the baseline after the therapy 
Fig. 1 - 4 summarize the mean changes of each drug from the baseline (0 M) to 3, 6, 9, and 
12 M in PVH 0-III. The data of memantine was omitted from Fig. 1 because there were only two cases 
(Table 2). As shown in Fig. 1, the PVH 0 subgroup preserved cognitive MMSE and HDS-R, affective 
GDS, AS, ABS, and ADL until 12 M of each drug treatment. An inter-drug comparison showed that 
MMSE was better preserved in the galantamine group (1.1 ± 4.0, * p < 0.05 vs donepezil) than in the 
donepezil group (-1.2 ± 1.9) at 9 M, while GDS was better preserved in the galantamine group (-0.8 ± 
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3.9) than in the rivastigmine group (1.2 ± 1.6, # p < 0.05 vs galantamine) at 9 M. 
Fig. 2 also shows the preservation of cognitive MMSE and HDS-R, and affective GDS and 
ABS until 12 M in the PVH I subgroup. AS showed an improvement from the baseline in the 
memantine group at 3 M (-9.0 ± 10.8, ¶ p < 0.05) and 9 M (-4.2 ± 5.9, ¶ p < 0.05) and in the 
galantamine group at 9 M (-2.5 ± 6.7, §§ p < 0.01). The donepezil group worsened in AS at 9 M from 
the baseline (4.3 ± 10.0, † p < 0.05). ADL worsened in the galantamine group (-0.9 ± 4.0, § p < 0.05) 
at 12 M. The inter-drug comparison showed an improvement of ABS in the memantine group (-5.4 ± 
4.2, * p < 0.05 vs donepezil) than in the donepezil group (0.4 ± 2.6) at 9 M. 
Fig. 3 shows well preserved affective GDS, AS, and ABS until 12 M in the PVH II 
subgroup. MMSE showed a significant improvement from the baseline in the galantamine group (1.5 
± 2.2, § p < 0.05) at 9 M and HDS-R (0.4 ± 3.7, § p < 0.05) at 3 M. However, the galantamine group 
showed a significant decline of ADL (-1.8 ± 2.6, § p < 0.05) at 12 M. The inter-drug comparison 
showed better preservation of MMSE in the galantamine group (1.5 ± 2.2, ** p < 0.01 vs donepezil) 
than in the donepezil group (-2.8 ± 2.4) at 9 M. 
As shown in Fig. 4, the PVH III subgroup showed well preserved MMSE, HDS-R, GDS, 
AS, and ABS until 12 M. ADL deteriorated in the riverstigmine group at 6 M (-3.3 ± 2.5, ‡ p < 0.05) 
and 12 M (-3.3 ± 2.7, ‡ p < 0.05). The inter-drug comparison showed better preservation of HDS-R in 
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the rivastigmine group (0.5 ± 4.5, ** p < 0.01 vs donepezil) and the galantamine group (-0.5 ± 5.4, * p 
< 0.05 vs donepezil) than in the donepezil group (-4.1 ± 4.6). 
 
 
Discussion 
In the present study, we evaluated the clinical features of AD patients who were divided 
into four subgroups according to the PVH grade (0-III). The baseline age became higher with PVH 
grades (Table 1), and cognitive scores (MMSE and HDS-R) showed a WM-severity-dependent 
decrease (Table 1). The ABS baseline of the rivastigmine group (PVH 0) and the memantine group 
(PVH I-II) was significantly higher than that of the donepezil group, while that of the memantine 
group was significantly higher than that of the galantamine group (Table 2). However, there were no 
significant differences in the baseline age and other baseline scores among the four drug groups (Table 
2). The PVH 0 subgroup showed preserved cognitive, affective, and ADL functions until 12 M in all 
four drug groups. After treatment with memantine and galantamine, AS improved significantly from 
the baseline in the PVH I subgroup while galantamine showed a worse ADL from the baseline (Fig. 2). 
In the PVH II subgroup, galantamine showed a significant improvement of cognitive scores (MMSE 
and HDS-R) from the baseline but a worse ADL from the baseline (Fig. 3). In the PVH III subgroup, 
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MMSE, HDS-R, GDS, AS, and ABS were well preserved in all four drug groups until 12 M, but ADL 
deteriorated in the riverstigmine group at 6 and 12 M (Fig. 4). 
Previous studies indicated that WMLs such as PVH and DWMH reflect demyelination, loss 
of ependymal cells, arteriosclerosis, and microinfarcts. PVH was associated with a loss of ventricular 
lining, and DWMH with deep WM demyelination 12-14. The volume of PVH was also associated with 
neurofibrillary tangles, indicating that the mechanism of AD may contribute to the vascular or white 
matter pathology 4. Our previous studies demonstrated that the severity of WMLs was closely related 
to a deterioration of the cognitive and affective functions in AD patients 5, 6. Moreover, PVH was 
related to a decline in cognitive function 15 and mental processing speed 16. In the present study, 
cognitive scores (MMSE and HDS-R) showed a WM-severity-dependent decrease with aging (Table 
1), suggesting that a worse PVH may reflect progression of AD pathology. 
The present study first described the clinical effect of four anti-dementia drugs on AD 
patients who were divided into four PVH-severity-dependent subgroups. The positive effect of 
galantamine in the PVH I-II subgroups may be consistent with a previous report, where galantamine 
was effective on cognitive, affective and ADL functions of AD accompanied by cerebrovascular 
disease 17 with increasing vascular reactivity 18 and regional cerebral blood flow 19. We have also 
previously reported that galantamine improved frontal lobe cognitive function in elderly AD patients 
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20, and maintained or improved cognitive, affective and ADL functions in AD with asymptomatic 
lacunar infarction 21. 
There are several reports that showed that donepezil was effective for both positive and 
negative affective symptoms 22-24. However, our present results showed that AS deteriorated at 9 M in 
the PVH I subgroup (Fig. 2). Similarly, rivastigmine was reported to be effective for cognitive and 
ADL functions in severe AD patients 25. However, our present results showed a deterioration of ADL 
at 6 and 12 M in the PVH III subgroup (Fig. 4). These discrepancies may be due to different severities 
of AD patients between previous and the present study and our PVH-severity-dependent analysis. 
Some reports showed significant effects of memantine in cognitive severe impairment battery (SIB) 
and ADCS-ADL for moderate to severe AD patients 15, 26. In agreement with our previous results 27, 28, 
the present study showed a significant improvement from the baseline in AS of the PVH I subgroup at 
3 and 9 M (Fig. 2). 
There are limitations to our retrospective study, considering nature of AD treatment, 
outcome of measurements would be evaluated in the longest observation time. In other words, 
different transient effect in one time point seems to be difficult to evaluate. 
In conclusion, the present study demonstrated that cognitive scores (MMSE and HDS-R) 
showed a WM-severity-dependent decreases with increasing age (Table 1). Moreover, the four drugs 
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showed WM-severity-dependent sensitivity when assessing the clinical effect of cognitive, affective 
and ADL functions.  
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Figure legends 
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Fig. 1)  The mean changes of clinical scores in each drug (donepezil, galantamine, and rivastigmine) 
from the baseline (0 M) to 3, 6, 9, and 12 M in the PVH 0 subgroup. Cognitive MMSE and HDS-R, 
affective GDS, AS, ABS, and ADL were well preserved until 12 M of each drug treatment.  
 
Fig. 2) The mean changes of clinical scores in each drug (donepezil, galantamine, rivastigmine, and 
memantine) from the baseline (0 M) to 3, 6, 9, and 12 M in the PVH I subgroup. AS showed 
improvements from the baseline in response to memantine at 3 and 9 M (¶ p < 0.05) and galantamine 
at 9 M (§§ p < 0.01).  
 
Fig. 3) The mean changes of clinical scores in each drug (donepezil, galantamine, rivastigmine, and 
memantine) from the baseline (0 M) to 3, 6, 9, and 12 M in the PVH II subgroup. MMSE showed a 
significant improvement from the baseline in response to galantamine (§ p < 0.05) at 9 M and HDS-R 
(§ p < 0.05) at 3 M.  
 
Fig. 4) The mean changes of clinical scores in each drug (donepezil, galantamine, rivastigmine, and 
memantine) from the baseline (0 M) to 3, 6, 9, and 12 M in the PVH III subgroup. ADL deteriorated 
in the riverstigmine group at 6 and 12 M (‡ p < 0.05). 
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Table 1
Baseline demographic and clinical characteristics of all AD patients and each subgroup according to Fazekas scale
 all AD patients  PVH 0  PVH I  PVH II  PVH III  p-value 
p-value 
for trend 
n 551  41 212 179 119 
Gender (male/female) 201/350  18/23 83/129 52/127 48/71 
Female (%) 63.5  56.1 60.8 70.9 59.7 0.084a 
Age (years) 78.4 ± 7.3  72.2 ± 8.1 77.5 ± 6.8 ** 79.6 ± 6.7 **## 80.5 ± 7.4 **## <0.001b 0.001c 
VSRAD 2.7 ± 1.3 2.6 ± 1.3 2.5 ± 1.1 2.7 ± 1.1 2.9 ± 1.6 
Baseline score 
  MMSE 20.1 ± 4.9  21.1 ± 4.2 21.0 ± 4.6 19.4 ± 5.3 # 19.2 ± 4.6 # 0.002b 0.001c 
  HDS-R 17.8 ± 5.9  19.2 ± 5.6 19.0 ± 5.7 16.7 ± 6.2 ## 16.7 ± 5.3 ## <0.001b 0.001c 
  GDS 5.3 ± 3.8  4.6 ± 3.7 5.1 ± 3.7 5.4 ± 3.8 6.0 ± 4.1 0.273b 
  AS 16.8 ± 9.4  15.1 ± 8.4 16.4 ± 9.7 16.9 ± 9.0 18.5 ± 9.5 0.226b 
  ABS 4.0 ± 5.5  4.6 ± 6.3 3.8 ± 5.2 3.9 ± 5.7 4.4 ± 5.6 0.706b 
  ADL 20.9 ± 5.8  21.6 ± 6.3  21.3 ± 5.7  20.4 ± 5.8  20.5 ± 5.9  0.442b 
a: χ2 test ** p<0.01 vs PVH 0 group 
b: Kruskal-Wallis test  #  p<0.05 vs PVH I group 
c: Jonkheere-Terpstra test ## p<0.01 vs PVH I group 
Table 2
Change of drug dosage and baseline demographic and clinical characteristics of AD patients
  donepezil  galantamine  rivastigmine  memantine  p-value 
             Dosage (mg/day) 
 3  months 5.5 ± 2.1 13.7 ± 5.0 10.9 ± 5.1 13.8 ± 5.7 
 6  months 6.2 ± 2.3 15.6 ± 5.4 12.3 ± 5.6 16.0 ± 5.1 
 9  months 6.4 ± 2.4 16.5 ± 5.4 13.4 ± 5.4 16.3 ± 5.0 
12 months 6.7 ± 2.4 17.2 ± 5.4 13.9 ± 5.3 17.3 ± 4.4 
PVH 0                  
n (3M, 6M, 9M, 12M) 11 (11, 10, 6, 5) 24 (24, 23, 22, 19) 4 (4, 3, 2, 2) 2 (2, 2, 2, 2) 
Gender (male/female) 2/9 10/14 3/1 2/0 
Female (%) 81.8 58.3 25.0 0 
Age (years) 69.9 ± 7.7 73.0 ± 8.8 71.3 ± 2.6 78.0 0.618 
Baseline score 
  MMSE 21.4 ± 4.3 20.4 ± 4.1 21.8 ± 1.3 27.0 0.704 
  HDS-R 20.3 ± 5.4 18.1 ± 5.6 20.0 ± 4.8 24.0 0.569 
  GDS 5.3 ± 4.6 5.0 ± 3.3 2.3 ± 2.9 2.0 0.366 
  AS 16.1 ± 8.9 16.1 ± 8.3 9.8 ± 5.9 9.5 0.519 
  ABS 2.1 ± 3.1 4.0 ± 15.5 12.3 ± 10.0 * 6.0 <0.05 
  ADL 24.2 ± 3.8 20.6 ± 7.1 21.6 ± 3.6 23.8 0.589 
PVH I                  
n (3M, 6M, 9M, 12M) 47 (47, 36, 32, 29) 133(133,124,106,84) 19 (19, 17 14, 12) 13 (13, 9, 7, 6) 
Gender (male/female) 16/31 52/81 10/9 5/8 
Female (%) 66.0 60.9 47.4 61.5 
Age (years) 77.8 ± 6.5 77.3 ± 7.0 76.8 ± 4.7 78.5 ± 7.7 0.664 
Baseline score 
  MMSE 21.9 ± 4.3 21.0 ± 4.4 20.3 ± 5.8 18.5 ± 4.8 0.207 
  HDS-R 19.5 ± 6.4 19.2 ± 5.1 19.3 ± 6.9 16.2 ± 5.9 0.268 
  GDS 5.0 ± 3.4 5.2 ± 3.9 3.9 ± 2.9 6.1 ± 3.4 0.488 
  AS 15.2 ± 7.3 16.8 ± 10.1 14.4 ± 7.2 19.0 ± 13.3 0.845 
  ABS 2.8 ± 3.9 3.2 ± 4.4 5.9 ± 7.6 9.8 ± 6.9 * # <0.01 
  ADL 21.4 ± 6.6 21.7 ± 5.5 20.0 ± 5.3 19.6 ± 4.9 
PVH II                 
n (3M, 6M, 9M, 12M) 46 (46, 35, 26, 20) 94 (94, 86, 70, 55) 31 (31, 25, 17, 12) 8 (8, 7, 6, 6) 
Gender (male/female) 14/32 31/63 5/26 2/6 
Female (%) 69.6 67.0 83.9 75.0 
Age (years) 78.0 ± 7.5 79.6 ± 6.2 81.5 ± 6.9 81.6 ± 3.6 0.235 
Baseline score 
  MMSE 19.7 ± 6.0 19.7 ± 4.9 17.3 ± 5.1 21.3 ± 4.0 0.051 
  HDS-R 16.1 ± 7.2 17.4 ± 5.8 15.0 ± 6.2 17.8 ± 4.6 0.263 
  GDS 5.4 ± 3.7 5.1 ± 4.1 6.4 ± 3.2 6.5 ± 2.8 0.414 
  AS 14.5 ± 7.9 16.6 ± 8.9 20.1 ± 8.7 21.5 ± 9.7 0.104 
  ABS 3.1 ± 5.4 3.5 ± 5.3 4.3 ± 4.2 12.0 ± 9.3 * <0.05 
   ADL 19.9 ± 5.3  20.9 ± 6.3  19.4 ± 3.8  19.3 ± 7.0  0.362 
PVH III 
n (3M, 6M, 9M, 12M) 22 (22, 18, 15, 8) 69 (69, 58, 51, 30) 19 (19, 15, 12, 6) 9 (9, 9, 7, 6) 
Gender (male/female) 7/15 30/39 8/11 3/6 
Female (%) 68.2 56.5 57.9 66.7 
Age (years) 80.3 ± 5.4 79.7 ± 8.9 82.8 ± 3.4 81.6 ± 4.5 0.283 
Baseline score 
  MMSE 17.4 ± 5.5 20.0 ± 4.2 18.3 ± 4.7 20.1 ± 3.3 0.235 
  HDS-R 14.5 ± 5.7 17.7 ± 4.9 15.6 ± 6.0 16.2 ± 3.8 0.196 
  GDS 6.0 ± 4.4 5.7 ± 3.9 8.9 ± 3.6 5.7 ± 3.7 0.316 
  AS 18.6 ± 10.2 17.8 ± 9.2 25.9 ± 8.5 13.0 ± 4.3 0.135 
  ABS 4.8 ± 6.5 3.9 ± 5.2 7.6 ± 6.4 3.3 ± 3.4 0.155 
   ADL 20.5 ± 5.8  21.1 ± 5.1  18.9 ± 8.1  16.8 ± 7.2  0.770 
* p<0.05 vs donepezil 
# p<0.05 vs galantamine 
